Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models

Therapeutic Targeting of Cancers with Loss of PTEN Function

(2014) Lloye Dillon et al.   CURRENT DRUG TARGETS

An Updated Report of the Trends in Cancer Incidence and Mortality in Japan

(2013) Kota Katanoda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer

(2013) Kyoichi Kaira et al.   LUNG CANCER

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

(2012) B. Besse et al.   ANNALS OF ONCOLOGY

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

(2012) A. Awada et al.   ANNALS OF ONCOLOGY

Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity

(2012) Emilia Montagna et al.   Clinical Breast Cancer

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

(2012) David S. Yoo et al.   CLINICAL CANCER RESEARCH

Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

(2012) P. Perez-Moreno et al.   CLINICAL CANCER RESEARCH

Beyond Bevacizumab: Antiangiogenic Agents

(2012) Shane Rogosin et al.   Clinical Lung Cancer

Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer

(2012) M. Catherine Pietanza et al.   Journal of Thoracic Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

(2012) Francesco Zappa et al.   LUNG CANCER

Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

(2012) J. Acquaviva et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of E7820, an Oral Inhibitor of Integrin  -2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

(2011) M. Mita et al.   CLINICAL CANCER RESEARCH

A Key Role for the Integrin α2β1 in Experimental and Developmental Angiogenesis

(2009) James D. San Antonio et al.   AMERICAN JOURNAL OF PATHOLOGY

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models

(2009) Tsuyoshi Suzuki et al.   CANCER SCIENCE

Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma

(2009) N. Schicher et al.   CLINICAL CANCER RESEARCH

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers

(2009) Guang Jin et al.   LUNG CANCER

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS